{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:25:55Z","timestamp":1767374755380},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T00:00:00Z","timestamp":1494374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Translational Research from Japanese Society of Circulation,"},{"name":"grant from Japan Agency for Medical Research and Development,"},{"name":"grant from Japan Research Foundation for Clinical Pharmacology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geriatrics Gerontology Int"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>In patients with diabetes or ischemia, angiogenesis and infection control are required for chronic leg ulcers, which substantially impair patients\u2019 quality of life. We developed a novel functional peptide, named AG30\/5C, with angiogenic and anti\u2010microbial properties. Treatment with AG30\/5C significantly accelerated the wound healing of full\u2010thickness defects in mice. To evaluate the safety of AG30\/5C in the treatment of leg ulcers, a physician\u2010initiated clinical study was carried out.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The first\u2010in\u2010human trial was designed as an open\u2010label treatment with AG30\/5C (0.1 mg\/mL) given twice per day for 11 days, and with a follow\u2010up period of 17 days. The inclusion criteria for severe skin ulcers were: (i) diabetes or critical limb ischemia; (ii) resistance to standard therapy for 1 month; and (iii) detection of methicillin\u2010resistant <jats:styled-content style=\"fixed-case\"><jats:italic>Staphylococcus aureus<\/jats:italic><\/jats:styled-content> in the skin ulcer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four patients were enrolled in this study, and two patients met these criteria. For the evaluation of safety, three adverse effects were reported as possibly related to AG30\/5C treatment; however, these adverse effects were not severe and resolved during or after treatment. Thus, there were no safety concerns. In both patients, the size of the ulcer decreased after treatment (44.62% and 10.23% decrease), and further decreased after the follow\u2010up period (73.85% and 10.23% decrease). The former patient was diagnosed as Werner syndrome and the skin ulcer was resistant to standard therapy; however, it was sensitive to AG30\/5C treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Topical treatment with AG30\/5C for severe leg ulcers was safe, well tolerated and effective. <jats:bold>Geriatr Gerontol Int 2017; 17: 2150\u20132156<\/jats:bold>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ggi.13051","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T06:42:45Z","timestamp":1494398565000},"page":"2150-2156","source":"Crossref","is-referenced-by-count":9,"title":["Physician\u2010initiated first\u2010in\u2010human clinical study using a novel angiogenic peptide, AG30\/5C, for patients with severe limb ulcers"],"prefix":"10.1111","volume":"17","author":[{"given":"Hironori","family":"Nakagami","sequence":"first","affiliation":[{"name":"Department of Health Development and Medicine, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Tanemura","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Takeya","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Kurinami","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Osaka University Hospital  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Tomono","sequence":"additional","affiliation":[{"name":"Division of Infection Control and Prevention, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Tamai","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Therapy Science, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Division of Gene Therapy Science, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn823"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-29916-5_4"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1180"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17545"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/71527"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00341.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2011.01406.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2008.10.009"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12476467"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASW.0000422628.63148.4b"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200404000-00004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2010.00765.x"},{"key":"e_1_2_7_14_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) Guidance for Industry;M3 (R2) nonclinical safety studies for the conduct of HUman clinical trials and marketing authorization for Phamaceuticals. Jan2010. (http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/)"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12513528"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.1.64"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(95)70245-8"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90143-Q"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092597"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12211"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.11.1.23"}],"container-title":["Geriatrics &amp; Gerontology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fggi.13051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ggi.13051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:50:38Z","timestamp":1695574238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ggi.13051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,10]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/ggi.13051"],"URL":"https:\/\/doi.org\/10.1111\/ggi.13051","archive":["Portico"],"relation":{},"ISSN":["1444-1586","1447-0594"],"issn-type":[{"value":"1444-1586","type":"print"},{"value":"1447-0594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,10]]}}}